<DOC>
	<DOC>NCT01100307</DOC>
	<brief_summary>The purpose of the study to assess the efficacy of pegaptanib sodium 0.3 mg comparing sham injection and to confirm safety of pegaptanib sodium 0.3 mg in subjects with diabetic macular edema.</brief_summary>
	<brief_title>A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema</brief_title>
	<detailed_description>During the study, an issue was reported concerning proper maintenance of treatment masking (See Result: Limitations and Caveats)</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<criteria>Type I, or Type II diabetic subjects Subjects must have macular edema that involves the center field of the macula 3. Foveal thickness of at least 250 Î¼m 4. Best corrected distance visual acuity in the study eye must be a letter score between 68 and 35 inclusive Eyes with prior panretinal photocoagulation (PRP) less than 4 months prior to baseline eyes in which PRP is needed now or is likely to be needed within the next 9 months HbA1C level &gt;12% or recent signs of uncontrolled diabetes Atrophy/scarring/fibrosis involving the center of the macula, including evidence of laser treated atrophy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>diabetic macular edema</keyword>
	<keyword>Macugen</keyword>
	<keyword>sham-controlled study</keyword>
</DOC>